Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

investors.com/news/technology/apogee-therapeutics-stock-eczema-treatment-dupixent-offering

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.
The post Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-10-09 17:03:49.
The Entire Business World on a Single Page. Free to Use →